Neurocrine Biosciences is dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's three late-stage clinical programs are elagolix, opicapone, and ingrezza, which are hormone-releasing antagonists for women's health, inhibitors for Parkinson's patients, and treatments for Tourette syndrome, respectively.